Treating anemia with erythropoiesis-stimulating agents: Effects on quality of life

Archives of Internal Medicine

Volumn 169, Issue 12, 2009, Pages 1100-1101

  Moossavi, Shahriar ^b   Freedman, Barry I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CARBOHYDRATE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEART LEFT VENTRICLE HYPERTROPHY; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MORTALITY; OPTIMAL DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; RISK REDUCTION; SLEEP DISORDER;

ANEMIA; ERYTHROPOIESIS; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 67649482425     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.159     Document Type: Editorial

References (17)

1. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20(9):1501-1510. (Pubitemid 39361354)
2. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol. 2007;78(3):183-205. (Pubitemid 46246531)
3. KDOQI National Kidney Foundation. NKF-K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5)(suppl 3):S11-S145.
4. Kazory A, Ross EA. Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol. 2009;53(8):639-647.
5. Wish JB, Coyne DW. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Mayo Clin Proc. 2007;82(11):1371-1380. (Pubitemid 350060134)
6. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17(4):1181-1191.
7. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584-590. (Pubitemid 28385655)
8. Drüeke TB, Locatelli F, Clyne N, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071-2084.
9. Singh AK, Szczech L, Tang KL, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098.
10. KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471-530.
11. Kausz AT, Solid C, Pereira BJ, Collins A, St Peter W. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease? Am J Kidney Dis. 2005;45(1):136-147.
12. Singh AK. The controversy surrounding hemoglobin and erythropoiesis- stimulating agents: what should we do now? Am J Kidney Dis. 2008;52(6)(suppl): S5-S13.
13. Clement FM, Klarenbach S, Tonelli M, Johnson JA, Mann BJ. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. Arch Intern Med. 2009;169(12):1104-1112.
14. Fukuhara S, Yamazaki S, Marumo F, et al. Health-related quality of life of predialysis patients with chronic renal failure. Nephron Clin Pract. 2007;105(1):c1-c8. (Pubitemid 46006566)
15. Lopes AA, Bragg-Gresham JL, Satayathum S, et al; Worldwide Dialysis Outcomes and Practice Patterns Study Committee. Health-related quality of life and associated outcomes among hemodialysis patients of different ethnicities in the United States: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2003;41(3):605-615.
16. Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int. 2009;75(1):15-24.
17. Frankenfield DL, Skellan D, Bachofer H, Rocco M, Straube B. Anemia management trending using CMS Claims Data, 2005-2007. J Am Soc Nephrol. 2009;19:730A.